Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA

Simon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, Remo Panaccione, Silvio Danese, Andreas Lazar, Anne M Robinson, Joel Petersson, Brandee L Pappalardo, Mareike Bereswill, Naijun Chen, Song Wang, Martha Skup, Roopal B Thakkar, Jingdong Chao, Simon Travis, Brian G Feagan, Laurent Peyrin-Biroulet, Remo Panaccione, Silvio Danese, Andreas Lazar, Anne M Robinson, Joel Petersson, Brandee L Pappalardo, Mareike Bereswill, Naijun Chen, Song Wang, Martha Skup, Roopal B Thakkar, Jingdong Chao

Abstract

Background and aims: Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health-related quality of life [HRQL] and health care costs in clinical practice.

Methods: InspirADA, a multicentre, prospective study, evaluated the effect of ADA in patients with moderate to severe UC treated according to usual clinical practice. Outcomes assessed were: Simple Clinical Colitis Activity Index [SCCAI] response/remission rates; changes in HRQL; all-cause direct costs; and UC-related direct and indirect costs from baseline to Week 26.

Results: Data from 463 patients were analysed. At Week 26, 67% (95% confidence interval [CI]: 62%, 71%) of patients achieved response; 48% [95% CI: 44%, 53%] were in remission. For the overall population, significant [all p < 0.001] improvements from baseline to Week 26 were observed for the Short Inflammatory Bowel Disease Questionnaire [SIBDQ] (mean change ± standard deviation [SD]: 17.4 ± 14.5) and the European Quality of Life-5 Dimensions-5 Level [EQ-5D-5L] (index: 0.1 ± 0.2; visual analogue scale [VAS]: 19.5 ± 25.8). Parallel improvements were seen in work productivity [11% absolute decrease in absenteeism; 25% absolute decrease in impairment while working; and 27% absolute decrease in impairment of ability to perform daily activities, all p < 0.001]. Among study completers, cumulative all-cause medical costs and UC-related medical costs were significantly [both p < 0.001] reduced by 59% and 77%, respectively, 6 months after initiation of therapy compared with the preceding 6 months. The safety profile of ADA was consistent with that observed in previous clinical trials.

Conclusions: ADA therapy in usual clinical practice is effective at improving and maintaining symptomatic control, improving HRQL, and decreasing costs of medical care among patients with UC.

Keywords: Ulcerative colitis; health care costs; patient outcomes.

© European Crohn’s and Colitis Organistion (ECCO) 2017.

Figures

Figure 1.
Figure 1.
Patient disposition. aA total of 80/463 patients discontinued adalimumab [ADA] owing to a lack of efficacy; of these, 66 patients discontinued ADA by Week 8.
Figure 2.
Figure 2.
[A] Percentage of patients who achieved SCCAI response and SCCAI remission after ADA therapy, and 95% CI. Clinical response was defined as a decrease of ≥ 2 points from baseline in SCCAI. Remission was defined as SCCAI ≤ 2. Missing data were imputed using NRI. [B] Percentage of patients with no blood in their stool after ADA therapy and 95% CI. Missing data were imputed using LOCF. Significant change [denoted by asterisk] from baseline [p < 0.001] using McNemar’s test was seen at Weeks 2, 8, and 26. SCCAI, Simple Clinical Colitis Activity Index; ADA, adalimumab; CI, confidence interval; NRI, non-responder imputation; LOCF, last observation carried forward.
Figure 3.
Figure 3.
Mean change from baseline in total SIBDQ score and 95% CI. Missing data were imputed using LOCF. A nine-point change in the SIBDQ is considered an MCID. Significant change [denoted by asterisk] from baseline [p < 0.001] using paired t test was seen at Weeks 2, 8, and 26. CI, confidence interval; MCID, minimal clinically important difference; SD, standard deviation; SIBDQ, Short Inflammatory Bowel Disease Questionnaire; LOCF, last observation carried forward.
Figure 4.
Figure 4.
Mean change from baseline to week 26 in WPAI and 95% CI. A decrease of 7% in WPAI outcome score for an individual patient is considered a MCID. Missing data were imputed using LOCF. Significant change [denoted by asterisk] from baseline [p < 0.001] using paired t test was observed for work time missed, impairment while working, overall work impairment, and activity impairment. Except for activity impairment, which was assessed for all patients, WPAI outcomes were assessed for employed patients only. MCID, minimal clinically important difference; SD, standard deviation; WPAI, Work Productivity and Activity Impairment; CI, confidence interval; LOCF, last observation carried forward.
Figure 5.
Figure 5.
Mean change from baseline to Week 26 in TSQM domain scores and 95% CI. Missing data were imputed using LOCF. Significant change [denoted by asterisk] from baseline [P < 0.001] was seen for all four TSQM domains using paired t test. SD, standard deviation; TSQM, Treatment Satisfaction Questionnaire for Medication; CI, confidence interval; LOCF, last observation carried forward.

References

    1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713–25.
    1. Dignass A, Eliakim R, Magro F et al. . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965–90.
    1. Dignass A, Lindsay JO, Sturm A et al. . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2012;6:991–1030.
    1. Van Assche G, Dignass A, Bokemeyer B et al. ; European Crohn’s and Colitis Organisation. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3: special situations. J Crohns Colitis 2013;7:1–33.
    1. Janke KH, Raible A, Bauer M et al. . Questions on life satisfaction [FLZM] in inflammatory bowel disease. Int J Colorectal Dis 2004;19:343–53.
    1. Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:272–86.
    1. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005;11:909–18.
    1. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14:554–65.
    1. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther 2010;31:693–707.
    1. van der Valk ME, Mangen MJ, Leenders M et al. ; COIN study group and the Dutch Initiative on Crohn and Colitis. Health care costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014;63:72–9.
    1. Reinisch W, Sandborn WJ, Hommes DW et al. . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780–7.
    1. Sandborn WJ, van Assche G, Reinisch W et al. . Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257–65.e1–3.
    1. Feagan BG, Sandborn WJ, Lazar A et al. . Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 2014;146:110–8.e3.
    1. Reinisch W, Sandborn WJ, Panaccione R et al. . 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013;19:1700–9.
    1. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10:1002–7; quiz e78.
    1. Bálint A, Farkas K, Palatka K et al. . Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohns Colitis 2016;10:26–30.
    1. Iborra M, Pérez-Gisbert J, Bosca-Watts MM et al. ; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis [GETECCU]. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol 2017;52:788–99.
    1. Sandborn WJ, Sakuraba A, Wang A et al. . Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 2016;32:1233–41.
    1. García-Bosch O, Gisbert JP, Cañas-Ventura A et al. . Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717–22.
    1. Taxonera C, Iglesias E, Muñoz F et al. . Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci 2017;62:481–90.
    1. Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol 2016;13:567–79.
    1. Higgins PD, Leung J, Schwartz M, Mapili J, Wren PA, Zimmermann EM. The quantitative validation of non-endoscopic disease activity indices in ulcerative colitis. Aliment Pharmacol Ther 2007;25:333–42.
    1. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005;54:782–8.
    1. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998;43:29–32.
    1. Jharap B, Sandborn WJ, Reinisch W et al. . Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2015;42:1082–92.
    1. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571–8.
    1. Jowett SL, Seal CJ, Barton JR, Welfare MR. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol 2001;96:2921–8.
    1. Lichtiger S, Binion DG, Wolf DC et al. . The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy. Aliment Pharmacol Ther 2010;32:1228–39.
    1. EuroQol. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
    1. EuroQol Group. EQ-5D-5L User Guide. Version 2.1 April 2015. Accessed December 2, 2015.
    1. Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn’s disease. Clin Ther 2008;30:393–404.
    1. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353–65.
    1. Binion DG, Louis E, Oldenburg B et al. . Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn’s disease: a meta-analysis. Can J Gastroenterol 2011;25:492–6.
    1. Atkinson MJ, Sinha A, Hass SL et al. . Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication [TSQM], using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12.
    1. Department of Health. Drugs and Pharmaceutical Electronic Market Information [eMit] Accessed September 8, 2016.
    1. Department of Health. UK National Schedule of Reference Costs 2012–13 for NHS Trusts and NHS Foundation Trusts 2013. Accessed October 2, 2014.
    1. Personal Social Services Research Unit. Unit Costs of Health and Social Care. 2013 Accessed October 2, 2014.
    1. Buckinghamshire Healthcare NHST Guideline 738FM.2. Adalimumab, Etanercept, Infliximab and Ustekinumab for the Treatment of Adults With Psoriasis. 2012 Accessed January 30, 2017.
    1. Office of National Statistics. Statistical Bulletin: Annual Survey of Hours and Earnings, 2014 Provisional Results 2014. Accessed December 7, 2014.
    1. Sandborn WJ, Colombel JF, D’Haens G et al. . One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204–13.
    1. Colombel JF, Sandborn WJ, Ghosh S et al. . Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109:1771–80.
    1. Ali T, Skup M, Yang M et al. . Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis. Am J Gastroenterol 2012;107:S641
    1. Ghosh S, Desjardins O, Skup M et al. . Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada. Value in Health 2014;17:A37.
    1. Beilman CL, Thanh NX, Ung V et al. . Real-life treatment paradigms show adalimumab is cost-effective for the management of ulcerative colitis. Can J Gastroenterol Hepatol 2016;2016:5315798.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner